Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
RemeGen Co Ltd (688331)
RemeGen Co Ltd stock price live, this page displays SS 688331 stock exchange data. View the 688331 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the RemeGen Co Ltd real time stock price chart below.
What Is the RemeGen Co Ltd Stock Price Today?
The RemeGen Co Ltd stock price today is 73.81.
What Is the Stock Symbol for RemeGen Co Ltd?
The stock symbol for RemeGen Co Ltd is "688331."
What Stock Exchange Does RemeGen Co Ltd Trade On?
RemeGen Co Ltd is listed and trades on the Shanghai stock exchange.
Is RemeGen Co Ltd a Good Stock to Buy?
Determining whether RemeGen Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 688331 quote. (ISIN: CNE100005B03)
What Is the RemeGen Co Ltd Stock Price Today?
The RemeGen Co Ltd stock price today is 73.81.
What Is the Stock Symbol for RemeGen Co Ltd?
The stock symbol for RemeGen Co Ltd is "688331."
What Stock Exchange Does RemeGen Co Ltd Trade On?
RemeGen Co Ltd is listed and trades on the Shanghai stock exchange.
Is RemeGen Co Ltd a Good Stock to Buy?
Determining whether RemeGen Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 688331 quote. (ISIN: CNE100005B03)
73.81
+3.82(+5.46%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
70.10
75.60
52 wk Range
22.37
79.50
688331 Scorecard
Full Analysis
Impressive gross profit margins
688331 is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
70.1075.60
52 wk Range
22.3779.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
688331 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
53.88
Downside
-27.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
RemeGen Co Ltd Company Profile
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company’s products under pre-clinical development include RC118, RC138, RC148, RC158, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
Compare 688331 to Peers and Sector
Metrics to compare | 688331 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688331PeersSector | |
|---|---|---|---|---|
P/E Ratio | −28.0x | −17.4x | −0.5x | |
PEG Ratio | −2.61 | 0.26 | 0.00 | |
Price/Book | 21.7x | 6.3x | 2.6x | |
Price / LTM Sales | 20.1x | 16.1x | 3.2x | |
Upside (Analyst Target) | −23.3% | 0.9% | 43.8% | |
Fair Value Upside | Unlock | −16.8% | 5.1% | Unlock |
Analyst Ratings
3 Buy
3 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 53.88
(-27.00% Downside)
Earnings
Latest Release
Apr 28, 2025
EPS / Forecast
-0.46 / --
Revenue / Forecast
525.97M / --
FAQ
What Is the RemeGen (688331) Stock Price Today?
The RemeGen stock price today is 73.81
What Stock Exchange Does RemeGen Trade On?
RemeGen is listed and trades on the Shanghai Stock Exchange stock exchange.
What Is the Stock Symbol for RemeGen?
The stock symbol for RemeGen is "688331."
What Is the RemeGen Market Cap?
As of today, RemeGen market cap is 39.20B.
What Is RemeGen's Earnings Per Share (TTM)?
The RemeGen EPS (TTM) is -2.54.
When Is the Next RemeGen Earnings Date?
RemeGen will release its next earnings report on 22 Aug 2025.
From a Technical Analysis Perspective, Is 688331 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has RemeGen Stock Split?
RemeGen has split 0 times.
How Many Employees Does RemeGen Have?
RemeGen has 2999 employees.
What is the current trading status of RemeGen (688331)?
As of 18 July 2025, RemeGen (688331) is trading at a price of 73.81, with a previous close of 69.99. The stock has fluctuated within a day range of 70.10 to 75.60, while its 52-week range spans from 22.37 to 79.50.
What Is RemeGen (688331) Price Target According to Analysts?
The average 12-month price target for RemeGen is CNY53.88167, with a high estimate of CNY60 and a low estimate of CNY40. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -27.00% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.